Drug Trial Radar · NCT05513001
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
Last checked: Nov 19, 2026Latest source record: Mar 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
696
Actual
Start
Dec 9, 2022
Primary completion
Aug 26, 2024
Study completion Aug 2, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Aug 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 core studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
Conditions
- Chronic Spontaneous Urticaria
Interventions
LOU064 (blinded)Drug
LOU064 (blinded) active treatment
PlaceboDrug
Placebo
LOU064 (open label)Drug
LOU064 (open-label) active treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first composite event (i.e., relapse (UAS7≥16)Time frame: 24 weeks
Locations
208 sites in 30 countries. Site status is shown where the registry gives one.
Allervie Clinical Research
Birmingham, Alabama
Cahaba Derm and skin hlth ctr 27
Birmingham, Alabama
Research Solutions of Arizona
Litchfield Park, Arizona
Acuro Research Inc
Little Rock, Arkansas
Arkansas Research Trials
North Little Rock, Arkansas
Kern Research
Bakersfield, California
Antelope Valley Clinical Trials
Lancaster, California
Allergy and Asthma Consultants
Redwood City, California
Asthma and Allergy Associates P C
Colorado Springs, Colorado
Colorado Allergy and Asthma Ctr PC
Denver, Colorado
UCONN Health Dermatology
Farmington, Connecticut
Florida Ctr Allergy Asthma Research
Aventura, Florida
Finlay Medical Research
Greenacres City, Florida
Miami Dade Medical Research
Miami, Florida
Sarasota Clinical Research
Sarasota, Florida
Allergy and Asthma Diagnostic Treatment Center
Tallahassee, Florida
Aeroallergy Research Laboratories
Savannah, Georgia
Treasure Valley Medical Research
Boise, Idaho
Endeavor Health
Glenview, Illinois
Asthma and Allergy Center of Chicago S C
River Forest, Illinois
Deaconess Clin Allerg Res Inst
Evansville, Indiana
The Indiana Clinical Trials Center
Plainfield, Indiana
Allergy and Asthma Specialist P S C
Owensboro, Kentucky
John Hopkins University
Baltimore, Maryland
Institute for Asthma and Allergy PC
Chevy Chase, Maryland
The Clinical Research Center
St Louis, Missouri
Somnos Clinical Research
Lincoln, Nebraska
Allergy Asthma Assoc Monmouth
Little Silver, New Jersey
Oakview Dermatology
Athens, Ohio
CR Services Acquisition US
Columbus, Ohio
Optimed Research LLC
Columbus, Ohio
Toledo Institute of Clinical Research
Toledo, Ohio
Allergy Asthma and Clinical Research
Oklahoma City, Oklahoma
Vital Prospects Clinical Research Institute
Tulsa, Oklahoma
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania
National Allergy and Asthma Research LLS
North Charleston, South Carolina
Orion Clinical Research
Austin, Texas
Western Sky Medical Research
El Paso, Texas
RFSA Dermatology
San Antonio, Texas
Allergy Associates of Utah
Sandy City, Utah
Showing 40 of 208 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.